Zheng Wang is counsel in the Hong Kong office of Latham & Watkins and a member of the Corporate Department.
Zheng represents clients on corporate and securities law matters, including US equity and debt registered offerings, Rule 144A/Regulation S equity and debt offerings, and private placements. She also has experience with convertible bonds, PIPEs, tender offers, and going private transactions. She has worked extensively across the Greater China region, particularly in the biotech, healthcare, technology, education, and real estate sectors. She has experience in advising Chinese issuers and international underwriters in capital markets transactions.
Firm recognized for advising Beijing-headquartered Sinovac on funding for COVID-19 vaccine development.